Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylnaltrexone for Opioid-Induced Constipation in Cancer Patients
NCT01004393Phase 2Completed
- Sponsor
- The University of Vermont
- Start
- Oct 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylnaltrexone in opioid-induced constipation (OIC), sponsored by The University of Vermont. Primary endpoint: Rescue-free Laxation After Administration of Subcutaneous Methylnaltrexone at 4 hours. Started Oct 2009; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01004393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004393.